What Attovia Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 9 | 9 |
| Sells | 46 | 46 |
| Total trades | 69 | 69 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 20,724,342 | 20,724,342 |
| Disposed | 211,614 | 211,614 |
| Net activity | +20,512,728 | +20,512,728 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Frazier Life Sciences XI, L.p. | 10% owner | Aug 06 | Open-market buy · P | +588,235 | $17.00 | +$10M | 6,154,213 |
| Frazier Life Sciences XI, L.p. | 10% owner | Aug 06 | Derivative Conversion · C | +961,322 | — | — | 5,565,978 |
| Frazier Life Sciences XI, L.p. | 10% owner | Aug 06 | Derivative Conversion · C | +1,189,940 | — | — | 4,604,656 |
| Frazier Life Sciences XI, L.p. | 10% owner | Aug 06 | Derivative Conversion · C | +1,590,175 | — | — | 3,414,716 |
| Frazier Life Sciences XI, L.p. | 10% owner | Aug 06 | Derivative Conversion · C | +1,749,192 | — | — | 1,824,541 |
| Redmile Group, Llc | 10% owner | Aug 06 | Open-market buy · P | +400,000 | $17.00 | +$6.8M | 1,182,854 |
| Redmile Group, Llc | 10% owner | Aug 06 | Open-market buy · P | +200,000 | $17.00 | +$3.4M | 982,854 |
| Redmile Group, Llc | 10% owner | Aug 06 | Derivative Conversion · C | +782,854 | — | — | 782,854 |
| Sanofi | 10% owner | Aug 06 | Open-market buy · P | +300,000 | $17.00 | +$5.1M | 1,082,855 |
| Sanofi | 10% owner | Aug 06 | Derivative Conversion · C | +782,855 | — | — | 782,855 |
| venBio Global Strategic Fund IV, L.p. | 10% owner | Aug 06 | Open-market buy · P | +382,352 | $17.00 | +$6.5M | 4,181,367 |
| venBio Global Strategic Fund IV, L.p. | 10% owner | Aug 06 | Derivative Conversion · C | +665,147 | — | — | 3,799,015 |
| venBio Global Strategic Fund IV, L.p. | 10% owner | Aug 06 | Derivative Conversion · C | +821,998 | — | — | 3,133,868 |
| venBio Global Strategic Fund IV, L.p. | 10% owner | Aug 06 | Derivative Conversion · C | +2,311,870 | — | — | 2,311,870 |
| Deep Track Biotechnology Master Fund, Ltd. | 10% owner | Aug 06 | Derivative Conversion · C | +1,957,138 | — | — | 1,957,138 |
| Walsh Colin | Director | Aug 06 | Open-market buy · P | +500,000 | $17.00 | +$8.5M | 3,020,632 |
| Walsh Colin | Director | Aug 06 | Derivative Conversion · C | +478,498 | — | — | 2,520,632 |
| Walsh Colin | Director | Aug 06 | Derivative Conversion · C | +1,957,134 | — | — | 2,042,134 |
| Goldman Sachs Group Inc | Insider | Aug 06 | Open-market buy · P | +500,000 | $17.00 | +$8.5M | 3,020,632 |
| Goldman Sachs Group Inc | Insider | Aug 06 | Derivative Conversion · C | +478,498 | — | — | 2,520,632 |
Loading...
